JP2005509003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509003A5 JP2005509003A5 JP2003543595A JP2003543595A JP2005509003A5 JP 2005509003 A5 JP2005509003 A5 JP 2005509003A5 JP 2003543595 A JP2003543595 A JP 2003543595A JP 2003543595 A JP2003543595 A JP 2003543595A JP 2005509003 A5 JP2005509003 A5 JP 2005509003A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- phenyl
- compound
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000001544 thienyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000002541 furyl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 150000002825 nitriles Chemical class 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- -1 sulfonylamino, aminosulfonyl Chemical group 0.000 claims 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004069 aziridinyl group Chemical group 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004276 dioxalanyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 claims 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 150000001266 acyl halides Chemical class 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001246 bromo group Chemical class Br* 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000001309 chloro group Chemical class Cl* 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical class F* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34463601P | 2001-11-09 | 2001-11-09 | |
| PCT/US2002/035494 WO2003041708A1 (en) | 2001-11-09 | 2002-11-05 | Benzimidazoles useful as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005509003A JP2005509003A (ja) | 2005-04-07 |
| JP2005509003A5 true JP2005509003A5 (enExample) | 2005-11-17 |
Family
ID=23351329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003543595A Pending JP2005509003A (ja) | 2001-11-09 | 2002-11-05 | タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6825219B2 (enExample) |
| EP (1) | EP1448199A1 (enExample) |
| JP (1) | JP2005509003A (enExample) |
| KR (1) | KR20040063144A (enExample) |
| CN (1) | CN1612733A (enExample) |
| BR (1) | BR0214019A (enExample) |
| CA (1) | CA2464419A1 (enExample) |
| CO (1) | CO5580788A2 (enExample) |
| EA (1) | EA200400595A1 (enExample) |
| HR (1) | HRP20040416A2 (enExample) |
| IL (1) | IL161516A0 (enExample) |
| MX (1) | MXPA04004301A (enExample) |
| NO (1) | NO20041887L (enExample) |
| NZ (1) | NZ533310A (enExample) |
| PL (1) | PL369771A1 (enExample) |
| WO (1) | WO2003041708A1 (enExample) |
| YU (1) | YU37904A (enExample) |
| ZA (1) | ZA200402947B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| FR2851563B1 (fr) * | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| FR2862971B1 (fr) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| US20050176792A1 (en) * | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| US20050209284A1 (en) * | 2004-02-12 | 2005-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tec kinase inhibitors |
| US8003806B2 (en) | 2004-11-12 | 2011-08-23 | OSI Pharmaceuticals, LLC | Integrin antagonists useful as anticancer agents |
| WO2006068105A1 (ja) * | 2004-12-20 | 2006-06-29 | Santen Pharmaceutical Co., Ltd. | 角結膜障害治療剤 |
| CA2600570C (en) | 2005-03-14 | 2011-12-06 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors |
| EP2527337A1 (en) * | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| GB0515025D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| US20080261975A1 (en) * | 2005-11-12 | 2008-10-23 | Joerg Martin Bentzien | Tec Kinase Inhibitors |
| WO2007133983A2 (en) * | 2006-05-08 | 2007-11-22 | Pharmacopeia, Inc. | 2-aminobenzimidazoles for treating neurodegenerative diseases |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
| BRPI0907925A2 (pt) * | 2008-02-25 | 2015-07-28 | Merck Patent Gmbh | Ativadores de glicoquinase. |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| EP2424533A4 (en) | 2009-04-27 | 2012-10-17 | High Point Pharmaceuticals Llc | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS |
| CA2792339A1 (en) | 2010-03-23 | 2011-09-29 | High Point Pharmaceuticals, Llc | Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors |
| KR20130108543A (ko) | 2010-08-05 | 2013-10-04 | 암젠 인코포레이션 | 역형성 림프종 키나제를 억제하는 벤즈이미다졸 및 아자벤즈이미다졸 화합물 |
| KR20180080358A (ko) | 2011-01-10 | 2018-07-11 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
| WO2013153539A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Tricyclic compounds as tec kinase inhibitors |
| US20150152083A1 (en) * | 2012-06-06 | 2015-06-04 | Irm Llc, A Delaware Limited Liability Company | Compounds and Compositions for Modulating EGFR Activity |
| JO3300B1 (ar) * | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| IL291945B2 (en) | 2012-11-01 | 2025-11-01 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015083059A1 (en) * | 2013-12-02 | 2015-06-11 | Novartis Ag | Forms of the egfr inhibitor |
| WO2015081463A1 (en) * | 2013-12-02 | 2015-06-11 | Novartis Ag | Egfr inhibitor forms |
| US10000469B2 (en) | 2014-03-25 | 2018-06-19 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| KR101560338B1 (ko) | 2014-04-21 | 2015-10-19 | 건국대학교 산학협력단 | 야누스 키나아제 1의 활성을 선택적으로 저해하는 벤조이미다졸 유도체 |
| ES2781474T3 (es) * | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| JP7313364B2 (ja) | 2018-02-21 | 2023-07-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体 |
| EP3946618A1 (en) * | 2019-04-05 | 2022-02-09 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
| JP7590996B2 (ja) | 2019-06-24 | 2024-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｅｇｆｒ阻害剤としての新たな大環状化合物および誘導体 |
| CN114591333B (zh) * | 2020-12-04 | 2023-08-01 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的制备方法 |
| CN116444544A (zh) * | 2022-01-10 | 2023-07-18 | 中国科学院上海药物研究所 | 苯并咪唑类化合物及其医药用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401171A (en) * | 1966-03-11 | 1968-09-10 | Smithkline Corp | 2-amidobenzimidazoles |
| CA1094061A (en) | 1976-03-19 | 1981-01-20 | Colin C. Beard | 5(6)-benzene ring substituted benzimidazole-2- carbamate derivatives having anthelmintic activity |
| US4191764A (en) | 1976-03-19 | 1980-03-04 | Syntex (U.S.A.) Inc. | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity |
| US4139626A (en) | 1976-03-19 | 1979-02-13 | Syntex (U.S.A.) Inc. | Anthelmintic 5(6)-benzene ring substituted benzimidazole-2-carbamates |
| US4312873A (en) | 1978-09-29 | 1982-01-26 | Syntex (U.S.A.) Inc. | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity |
| AU632288B2 (en) | 1988-09-12 | 1992-12-24 | Pharmacia & Upjohn Company | Novel cc-1065 analogs having two cpi subunits |
| JPH06759B2 (ja) | 1989-09-22 | 1994-01-05 | ファイザー製薬株式会社 | 新規なベンゾイミダゾール化合物 |
| GB9107398D0 (en) | 1991-04-09 | 1991-05-22 | British Bio Technology | Compounds |
| JP2729545B2 (ja) | 1991-06-05 | 1998-03-18 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法 |
| CA2116863A1 (en) | 1992-07-03 | 1994-01-20 | Sumio Yokota | Condensed heterocyclic derivatives and herbicides |
| CA2144763A1 (en) | 1992-10-14 | 1994-04-28 | George D. Hartman | Fibrinogen receptor antagonists |
| DE4304650A1 (de) | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| IL135176A0 (en) * | 1997-11-10 | 2001-05-20 | Bristol Myers Squibb Co | Benzothiazole derivatives and pharmaceutical compositions containing the same |
| WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
| ES2225231T3 (es) * | 1999-10-06 | 2005-03-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas. |
| US6660870B1 (en) | 2000-03-17 | 2003-12-09 | Alcon, Inc. | 2-acylaminobenzimidazole derivatives for treating glaucoma |
| US6903126B2 (en) | 2001-07-09 | 2005-06-07 | Schering Ag | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
-
2002
- 2002-11-05 HR HR20040416A patent/HRP20040416A2/hr not_active Application Discontinuation
- 2002-11-05 EA EA200400595A patent/EA200400595A1/ru unknown
- 2002-11-05 BR BR0214019-5A patent/BR0214019A/pt not_active Application Discontinuation
- 2002-11-05 KR KR10-2004-7007023A patent/KR20040063144A/ko not_active Withdrawn
- 2002-11-05 PL PL02369771A patent/PL369771A1/xx not_active Application Discontinuation
- 2002-11-05 MX MXPA04004301A patent/MXPA04004301A/es unknown
- 2002-11-05 YU YU37904A patent/YU37904A/sh unknown
- 2002-11-05 US US10/288,362 patent/US6825219B2/en not_active Expired - Lifetime
- 2002-11-05 EP EP02789445A patent/EP1448199A1/en not_active Withdrawn
- 2002-11-05 JP JP2003543595A patent/JP2005509003A/ja active Pending
- 2002-11-05 CA CA002464419A patent/CA2464419A1/en not_active Abandoned
- 2002-11-05 IL IL16151602A patent/IL161516A0/xx unknown
- 2002-11-05 CN CNA028270002A patent/CN1612733A/zh active Pending
- 2002-11-05 WO PCT/US2002/035494 patent/WO2003041708A1/en not_active Ceased
- 2002-11-05 NZ NZ533310A patent/NZ533310A/xx unknown
-
2004
- 2004-04-19 ZA ZA200402947A patent/ZA200402947B/en unknown
- 2004-05-07 NO NO20041887A patent/NO20041887L/no unknown
- 2004-06-01 CO CO04051014A patent/CO5580788A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005509003A5 (enExample) | ||
| JP6017313B2 (ja) | 化合物および方法 | |
| CA2834928C (en) | Compounds for inflammation and immune-related uses | |
| JP2007536231A5 (enExample) | ||
| AU2007236707B2 (en) | Hetero compound | |
| ES2442003T3 (es) | Nuevo derivado de sulfonamida de ácido malónico y uso farmacéutico del mismo | |
| JP5582634B2 (ja) | ４−置換フェノキシフェニル酢酸誘導体 | |
| WO2015054960A1 (zh) | 痛风治疗药Lesinurad的制备方法及Lesinurad中间体 | |
| CA2894016A1 (en) | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| CA2228050A1 (en) | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use | |
| CA2787121A1 (en) | Aminopyridine derivatives as anti-malarial agents | |
| US20150299192A1 (en) | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | |
| WO2015145371A1 (en) | Ror-gamma modulators and uses thereof | |
| JP2006524222A5 (enExample) | ||
| CN107207489A (zh) | 作为nadph氧化酶抑制剂的酰氨基噻二唑衍生物 | |
| JP2000515133A (ja) | 血糖降下性および脂質低下性の化合物 | |
| RU2006102127A (ru) | Производные хинолина и их применение в терапии | |
| HK1220195A1 (zh) | 恶唑及异恶唑钙释放激活的钙调节剂 | |
| JP2008509955A5 (enExample) | ||
| JP2019520317A (ja) | ベンゾイルグリシン誘導体およびその作製および使用の方法 | |
| JP2007537255A5 (enExample) | ||
| JP2024543207A (ja) | 新規ｈｄａｃ阻害剤及びその治療的使用 | |
| JP2004518742A5 (enExample) | ||
| EP2978750B1 (en) | "synthesis of dabigatran" | |
| JP2005508954A5 (enExample) |